Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
FindCure Biosciences (ZhongShan) Co., Ltd.
Eastern Cooperative Oncology Group
Kaiser Permanente
University of Colorado, Denver
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company
Bayer
UNC Lineberger Comprehensive Cancer Center
Eli Lilly and Company
Actym Therapeutics, Inc.
M.D. Anderson Cancer Center
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine
Jonsson Comprehensive Cancer Center
Sichuan Enray Pharmaceutical Sciences Company
Eli Lilly and Company
ModeX Therapeutics, An OPKO Health Company
University of Alabama at Birmingham
TransThera Sciences (Nanjing), Inc.
Instituto do Cancer do Estado de São Paulo
Columbia University
Theratechnologies
Cedars-Sinai Medical Center
Cedars-Sinai Medical Center
Algemeen Ziekenhuis Maria Middelares
Universidade Federal de Pernambuco
Sotio Biotech Inc.
Salubris Biotherapeutics Inc
NantCell, Inc.
TransThera Sciences (Nanjing), Inc.
Istituti Clinici Scientifici Maugeri SpA
M.D. Anderson Cancer Center
University Medical Center Groningen
Kineta Inc.
Institut Bergonié
Blue Note Therapeutics
MacroGenics
Celgene
Pfizer
Amgen
SWOG Cancer Research Network
University of Alabama at Birmingham
Memorial Sloan Kettering Cancer Center
Valerio Therapeutics
Valerio Therapeutics
University of Chicago
Calando Pharmaceuticals
National Cancer Institute (NCI)
National Cancer Institute (NCI)